Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.28)
# 2,642
Out of 4,918 analysts
23
Total ratings
50%
Success rate
9.71%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $20.80 | +49.04% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $4.19 | +198.33% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $11.42 | +9.46% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $2.36 | +154.24% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.46 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $15.16 | +64.91% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $240 | $3.90 | +6,053.85% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.58 | +448.89% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $7.16 | +221.45% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.40 | +1,614.29% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $2.38 | +83,933.61% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.69 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $20.80
Upside: +49.04%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $4.19
Upside: +198.33%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $11.42
Upside: +9.46%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $2.36
Upside: +154.24%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.46
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $15.16
Upside: +64.91%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $240
Current: $3.90
Upside: +6,053.85%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.58
Upside: +448.89%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $7.16
Upside: +221.45%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.40
Upside: +1,614.29%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $2.38
Upside: +83,933.61%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.69
Upside: -